Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers is a dataset published in Proceedings of the National Academy of Sciences (2020). On theSindex it has a DataRank of 2.1, placing it in the top 9.9% of the data-sharing corpus. It has been cited 74 times, with 64 citing works in its 1-hop citation network. Its calibrated FAIR score is 60/100.
Ranks in the top 10% for downstream scientific impact
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
Full FAIR picture · advisory
The headline score is computed from the scored criteria — the fact-shaped checks (a repository, an accession, a licence) that two independent models agree on. The advisory criteria below are real FAIR guidance but rest on judgment calls that models read differently, so they inform without moving the number.
“accession no. GSE141633”
The paper provides a GEO accession, which is a persistent identifier scheme recognized at the 'yes' level. [majority verdict 'yes' (4/5 passes agreed)]
RDA-F1-01D — FAIR Data Maturity Model: 'Data is identified by a persistent identifier' (priorit · RDA-F1-02D — FAIR Data Maturity Model: 'Data is identified by a globally unique identifier' · FsF-F1-02D — F-UJI/FAIRsFAIR: 'Data is assigned a persistent identifier'
“Gene Expression Omnibus (GEO) database”
The paper names GEO, a data repository, as the holder of the data. [majority verdict 'yes' (4/5 passes agreed)]
RDA-F4-01M — FAIR Data Maturity Model: metadata is offered so it can be harvested and indexed ( · NIH DMS Policy Element 4 (NOT-OD-21-014) — name the repository where data will be archived · NSTC Desirable Characteristics of Data Repositories (2022) — 'Long-Term Sustainability', 'Reten
“Raw sequencing files (fastq) from the engineered cell lines and gene expression matrices are available through Gene Expression Omnibus (accession no. GSE141633).”— not found in the paper; verdict downgraded
The dataset identifier appears only in the body text, not in the reference list. [downgraded to 'no' — no verifiable quote from the paper] [majority verdict 'no' (2/5 passes agreed)]
FORCE11 Joint Declaration of Data Citation Principles (2014) — data should be cited as a first- · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes · FsF-F3-01M — F-UJI: 'Metadata includes the identifier of the data it describes'
Advisory · not in the published score
“Raw sequencing files (fastq) from the engineered cell lines and gene expression matrices are available through Gene Expression Omnibus (accession no. GSE141633)”— not found in the paper; verdict downgraded
The data availability statement points to a repository record with an accession number, corresponding to Colavizza category 3. [downgraded to 'partial' — no verifiable quote from the paper]
Colavizza, Hrynaszkiewicz, Staden, Whitaker & McGillivray (2020), 'The citation advantage of li · Springer Nature research data policy — Data Availability Statements: standard statement templat · RDA-F3-01M — metadata clearly and explicitly includes the identifier of the data it describes
“Raw sequencing files (fastq) from the engineered cell lines and gene expression matrices are available through Gene Expression Omnibus (accession no. GSE141633)”— not found in the paper; verdict downgraded
The dataset content is described in running prose rather than an itemised inventory, section, or table. [downgraded to 'no' — no verifiable quote from the paper]
RDA-F2-01M — 'Rich metadata is provided to allow discovery' (priority Essential) · FsF-F2-01M — F-UJI: 'Metadata includes descriptive core elements to support data findability' · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data'
“Raw sequencing files (fastq) from the engineered cell lines and gene expression matrices are available through Gene Expression Omnibus (accession no. GSE141633)”— not found in the paper; verdict downgraded
The paper provides a route to the data with no stated precondition; they are publicly available in GEO. [downgraded to 'partial' — no verifiable quote from the paper]
RDA-A1.1-01D — 'Data is accessible through a free access protocol' · FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · NSTC Desirable Characteristics of Data Repositories (2022) — 'Free and Easy Access'
Advisory · not in the published score
The paper states that the data are available through GEO but does not explicitly label the access level as 'open access' or similar. [downgraded to 'no' — no verifiable quote from the paper]
FsF-A1-01M — F-UJI: 'Metadata contains access level and access conditions of the data' · RDA-A1-01M — metadata contains information to enable the user to get access to the data · COAR Controlled Vocabularies — Access Rights v1.0 (open / embargoed / restricted / metadata-onl
The paper's own data are from engineered cell lines and are deposited in GEO with no mention of sensitivity or controlled access; no gatekeeper is named.
NIH Genomic Data Sharing Policy (NOT-OD-14-124) — controlled-access via a Data Access Committee · RDA-A1.2-01D — 'Data is accessible through an access protocol that supports authentication and · NIH DMS Policy Element 5 (NOT-OD-21-014) — Access, Distribution, or Reuse Considerations (conse
The paper does not state how long the data will be retained or any persistence commitment. [majority verdict 'no' (4/5 passes agreed)]
NIH DMS Plan Element 4 (NOT-OD-21-014) — Data Preservation, Access, and Associated Timelines · NSTC Desirable Characteristics (2022), Organizational Infrastructure: 'Retention Policy' · RDA-A2-01M — 'Metadata is guaranteed to remain available after data is no longer available'
“fastq”— not found in the paper; verdict downgraded
The paper names FASTQ, an open community-standard format, for the released data. [downgraded to 'partial' — no verifiable quote from the paper] [majority verdict 'partial' (4/5 passes agreed)]
FsF-R1.3-02D — F-UJI: 'Data is available in a file format recommended by the target research co · RDA-R1.3-02D — data is expressed in a machine-understandable community standard · RDA-I1-01D — data uses a knowledge representation expressed in a standardised format
Advisory · not in the published score
“The genome annotation file was downloaded from GENCODE V26 (86) under human genome version hg19 (GRCh37).”— not found in the paper; verdict downgraded
The paper names GENCODE, a community-standard data annotation resource. [downgraded to 'partial' — no verifiable quote from the paper] [majority verdict 'partial' (3/5 passes agreed)]
RDA-R1.3-01M — 'Metadata complies with a community standard' (priority Essential) · RDA-R1.3-01D — 'Data complies with a community standard' · RDA-I2-01M — '(Meta)data use vocabularies that follow FAIR principles'
“accession no. phs000424”
The paper provides dbGaP accessions for external datasets used in the analysis, which are identifiers for resources other than the paper's own data.
RDA-I3-01M — '(meta)data include references to other (meta)data' · RDA-I3-03M — 'metadata includes qualified references to other metadata' · FsF-I3-01M — F-UJI: 'Metadata includes links between the data and its related entities'
The paper does not state any license for the deposited data; the article license (CC BY-NC-ND) does not apply to the data.
RDA-R1.1-01M — 'Metadata includes information about the licence under which the data can be reu · RDA-R1.1-02M — 'Metadata refers to a standard reuse licence' · RDA-R1.1-03M — 'Metadata refers to a machine-understandable reuse licence'
“Deposited 9 December 2019”
The paper provides a deposit date but no version token for the data. [majority verdict 'partial' (4/5 passes agreed)]
DataCite Metadata Schema 4.6 — the 'Version' property · RDA-R1.2-01M — provenance information (which version was used is provenance) · NSTC Desirable Characteristics of Data Repositories (2022) — 'Provenance', 'Retention Policy'
“https://github.com/Xinglab/PEGASAS”
The paper gives GitHub URLs for the code, which are machine-resolvable locators.
NIH DMS Policy Element 2 (NOT-OD-21-014) — 'Related Tools, Software and/or Code' · FAIR4RS Principles v1.0 (Chue Hong et al., 2022; RDA/FORCE11/ReSA) — FAIR Principles for Resear · FORCE11 Software Citation Principles (Smith, Katz & Niemeyer, 2016, PeerJ CS 2:e86)
“R01CA220238”
The paper lists specific grant numbers alongside funder names.
DataCite Metadata Schema 4.6 — 'FundingReference' property (funderName, funderIdentifier, award · Crossref Funder Registry — canonical funder identifiers for funding metadata · RDA-F2-01M — rich metadata provided to allow discovery (funding is part of the descriptive reco
Advisory · not in the published score
“STAR 2.5.3a”— not found in the paper; verdict downgraded
The paper names specific software with version numbers used to produce the data. [downgraded to 'partial' — no verifiable quote from the paper] [majority verdict 'partial' (4/5 passes agreed)]
RDA-R1.2-01M — 'Metadata includes provenance information according to community- specific standa · FsF-R1.2-01M — F-UJI: 'Metadata includes provenance information about data creation or generati · W3C PROV-O (W3C Recommendation, 2013) — the entity/activity/agent model of provenance
“Dataset S1”— not found in the paper; verdict downgraded
The paper references Dataset S1 as a supplementary table containing variable definitions, but this is inside the article (not shipped with the data). [downgraded to 'no' — no verifiable quote from the paper]
RDA-R1-01M — '(Meta)data are richly described with a plurality of accurate and relevant attribu · FsF-R1-01MD — F-UJI: 'Metadata specifies the content of the data' · NIH DMS Policy Element 3 (NOT-OD-21-014) — Standards (documentation and metadata to accompany t
Calibrated FAIR score — a parallel quality metric, independent of the DataRank citation score. See the full evaluation →
Base Score Contribution
0.648
From this paper's citation signal
Citation Network Contribution
1.5
From 53 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 64 citers.
UCLA Tumor Cell Biology Training Grant
Grant: T32CA009056
Office of the Assistant Secretary of Defense for Health Affairs Prostate Cancer Research Program
Grant: W81XWH-16-1-0216
HHS | NIH | National Cancer Institute
Grant: R01CA220238
HHS | NIH | National Cancer Institute
Grant: U01CA233074
HHS | NIH | National Cancer Institute
Grant: U24CA232979
HHS | NIH | National Cancer Institute
Grant: P50CA092131
Parker Institute for Cancer Immunotherapy
Grant: 20163828
NCI NIH HHS
Grant: P30 CA016042
FWCI
3.07
Citation Percentile
0.9%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 2 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 2 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 1 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 1 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 3 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 3 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 4 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 2 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 2 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 4 of PARP4 interacts with hnRNPM to regulate splicing during lung cancer progression
Additional file 3 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 5 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 3 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 4 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 4 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 5 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 1 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer
Additional file 1 of Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer